AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.
AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees.
We have two Business Units each responsible for their respective sales, marketing and Research and Development (R&D) activities. Both Business Units focus on a different strategic route to market.
- Surgical Business Unit – Focus on selling, marketing and innovation of all AMS branded products. These are sold directly and through distributors.
- Woundcare Business Unit – Focus on distribution, marketing and innovation of products that are supplied to medical device partners under their own brands.
We operate in the global tissue-healing technologies market. The market is growing steadily, driven by an increasingly ageing population and advances in technology. An overview is shown below.